QQQ   359.07 (+0.30%)
AAPL   171.27 (+0.34%)
MSFT   317.05 (+1.09%)
META   303.33 (-0.21%)
GOOGL   131.64 (-0.51%)
AMZN   127.32 (+1.06%)
TSLA   250.94 (+1.85%)
NVDA   436.03 (+1.19%)
NIO   9.04 (+1.46%)
BABA   86.86 (+1.54%)
AMD   103.50 (+0.72%)
T   14.97 (-0.27%)
F   12.49 (-0.56%)
MU   67.76 (+3.93%)
CGC   0.80 (-2.22%)
GE   110.34 (-1.78%)
DIS   80.71 (+0.72%)
AMC   8.10 (+3.98%)
PFE   33.01 (+2.87%)
PYPL   58.40 (+0.38%)
NFLX   376.74 (+0.10%)
QQQ   359.07 (+0.30%)
AAPL   171.27 (+0.34%)
MSFT   317.05 (+1.09%)
META   303.33 (-0.21%)
GOOGL   131.64 (-0.51%)
AMZN   127.32 (+1.06%)
TSLA   250.94 (+1.85%)
NVDA   436.03 (+1.19%)
NIO   9.04 (+1.46%)
BABA   86.86 (+1.54%)
AMD   103.50 (+0.72%)
T   14.97 (-0.27%)
F   12.49 (-0.56%)
MU   67.76 (+3.93%)
CGC   0.80 (-2.22%)
GE   110.34 (-1.78%)
DIS   80.71 (+0.72%)
AMC   8.10 (+3.98%)
PFE   33.01 (+2.87%)
PYPL   58.40 (+0.38%)
NFLX   376.74 (+0.10%)
QQQ   359.07 (+0.30%)
AAPL   171.27 (+0.34%)
MSFT   317.05 (+1.09%)
META   303.33 (-0.21%)
GOOGL   131.64 (-0.51%)
AMZN   127.32 (+1.06%)
TSLA   250.94 (+1.85%)
NVDA   436.03 (+1.19%)
NIO   9.04 (+1.46%)
BABA   86.86 (+1.54%)
AMD   103.50 (+0.72%)
T   14.97 (-0.27%)
F   12.49 (-0.56%)
MU   67.76 (+3.93%)
CGC   0.80 (-2.22%)
GE   110.34 (-1.78%)
DIS   80.71 (+0.72%)
AMC   8.10 (+3.98%)
PFE   33.01 (+2.87%)
PYPL   58.40 (+0.38%)
NFLX   376.74 (+0.10%)
QQQ   359.07 (+0.30%)
AAPL   171.27 (+0.34%)
MSFT   317.05 (+1.09%)
META   303.33 (-0.21%)
GOOGL   131.64 (-0.51%)
AMZN   127.32 (+1.06%)
TSLA   250.94 (+1.85%)
NVDA   436.03 (+1.19%)
NIO   9.04 (+1.46%)
BABA   86.86 (+1.54%)
AMD   103.50 (+0.72%)
T   14.97 (-0.27%)
F   12.49 (-0.56%)
MU   67.76 (+3.93%)
CGC   0.80 (-2.22%)
GE   110.34 (-1.78%)
DIS   80.71 (+0.72%)
AMC   8.10 (+3.98%)
PFE   33.01 (+2.87%)
PYPL   58.40 (+0.38%)
NFLX   376.74 (+0.10%)
NASDAQ:ESPR

Esperion Therapeutics (ESPR) Stock Forecast, Price & News

$0.99
+0.03 (+3.14%)
(As of 12:56 PM ET)
Compare
Today's Range
$0.96
$1.00
50-Day Range
$0.96
$1.79
52-Week Range
$0.85
$8.87
Volume
634,943 shs
Average Volume
3.28 million shs
Market Capitalization
$105.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.88

Esperion Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
1,013.0% Upside
$10.88 Price Target
Short Interest
Bearish
15.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.76
Upright™ Environmental Score
News Sentiment
-0.02mentions of Esperion Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$1,438 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.98) to ($0.05) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

612th out of 970 stocks

Pharmaceutical Preparations Industry

296th out of 454 stocks


ESPR stock logo

About Esperion Therapeutics (NASDAQ:ESPR) Stock

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

ESPR Price History

ESPR Stock News Headlines

This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
5 Analysts Have This to Say About Esperion Therapeutics
Esperion Therapeutics Q2 2023 Earnings Preview
H.C. Wainwright Keeps Their Buy Rating on Esperion (ESPR)
Esperion (ESPR) Gets a Buy from JMP Securities
Analyst Expectations for Esperion Therapeutics's Future
H.C. Wainwright Sticks to Its Buy Rating for Esperion (ESPR)
See More Headlines
Receive ESPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ESPR Company Calendar

Last Earnings
8/01/2023
Today
9/29/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ESPR
Fax
N/A
Employees
199
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.88
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+1,035.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-233,660,000.00
Net Margins
-252.82%
Pretax Margin
-252.82%

Debt

Sales & Book Value

Annual Sales
$75.47 million
Book Value
($4.39) per share

Miscellaneous

Free Float
106,352,000
Market Cap
$102.50 million
Optionable
Optionable
Beta
0.13
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Sheldon L. Koenig (Age 57)
    Pres, CEO & Director
    Comp: $1.2M
  • Mr. Benjamin O. Looker (Age 41)
    Gen. Counsel
    Comp: $550.35k
  • Dr. JoAnne Micale Foody FACC (Age 57)
    M.D., Chief Medical Officer
    Comp: $771.19k
  • Mr. Benjamin Halladay M.B.A. (Age 37)
    Chief Financial Officer
  • Mr. Glenn P. Brame (Age 65)
    Chief Technical Operations Officer
  • Tiffany Aldrich M.B.A.
    Associate Director of Corp. Communications
  • Ms. Betty Jean Swartz
    Chief Strategy Officer
  • Mr. Eric J. Warren R.Ph. (Age 51)
    Chief Commercial Officer













ESPR Stock - Frequently Asked Questions

Should I buy or sell Esperion Therapeutics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ESPR shares.
View ESPR analyst ratings
or view top-rated stocks.

What is Esperion Therapeutics' stock price forecast for 2023?

9 equities research analysts have issued 12 month target prices for Esperion Therapeutics' stock. Their ESPR share price forecasts range from $4.00 to $22.00. On average, they predict the company's stock price to reach $10.88 in the next twelve months. This suggests a possible upside of 1,035.2% from the stock's current price.
View analysts price targets for ESPR
or view top-rated stocks among Wall Street analysts.

How have ESPR shares performed in 2023?

Esperion Therapeutics' stock was trading at $6.23 at the beginning of 2023. Since then, ESPR stock has decreased by 84.6% and is now trading at $0.9580.
View the best growth stocks for 2023 here
.

Are investors shorting Esperion Therapeutics?

Esperion Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 16,460,000 shares, an increase of 8.4% from the August 31st total of 15,180,000 shares. Based on an average daily volume of 3,500,000 shares, the short-interest ratio is presently 4.7 days. Approximately 15.5% of the shares of the stock are sold short.
View Esperion Therapeutics' Short Interest
.

When is Esperion Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our ESPR earnings forecast
.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings results on Tuesday, August, 1st. The biopharmaceutical company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.15. The biopharmaceutical company had revenue of $25.79 million for the quarter, compared to the consensus estimate of $24.64 million. The company's revenue was up 36.9% on a year-over-year basis. During the same period last year, the business earned ($1.05) earnings per share.

What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?

20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

How do I buy shares of Esperion Therapeutics?

Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $0.96.

How much money does Esperion Therapeutics make?

Esperion Therapeutics (NASDAQ:ESPR) has a market capitalization of $102.50 million and generates $75.47 million in revenue each year. The biopharmaceutical company earns $-233,660,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis.

How many employees does Esperion Therapeutics have?

The company employs 199 workers across the globe.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The official website for the company is www.esperion.com. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at ir@esperion.com.

This page (NASDAQ:ESPR) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -